![]() Fall in LDL level in the pravastatin-treated group did not correlate with CHD risk reduction in multivariate regression. Variation in plasma lipids at baseline did not influence the relative risk reduction generated by pravastatin therapy. Methods and Results-Relationships between baseline lipid concentrations and incidence of all cardiovascular events and between on-treatment lipid concentrations and risk reduction in patients taking pravastatin were examined by use of Cox regression models and by division of the cohort into quintiles. The present analysis examines the extent to which differences in LDL and other plasma lipids both at baseline and on treatment influenced CHD risk reduction. Customer Service and Ordering Informationīackground-The West of Scotland Coronary Prevention Study was a primary prevention trial that demonstrated the effectiveness of pravastatin (40 mg/d) in reducing morbidity and mortality from coronary heart disease (CHD) in moderately hypercholesterolemic men.Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA). ![]()
0 Comments
Leave a Reply. |